Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain: Results From...

Area of Science:

• Dermatology
• Pharmacology
• Clinical Practice Research

Background:

• Psoriasis is a chronic inflammatory skin condition impacting quality of life.
• Apremilast is an oral treatment option for moderate to severe plaque psoriasis.
• Real-world data on apremilast use in clinical practice is valuable for understanding its effectiveness and patient experience.

Purpose of the Study:

• To describe characteristics of psoriasis patients treated with apremilast in Spain.
• To evaluate patient and dermatologist perspectives on apremilast therapy.
• To assess apremilast outcomes in a real-world clinical setting.

Main Methods:

• An observational, retrospective, multicenter study design.
• Inclusion of patients with chronic plaque psoriasis treated with apremilast.
• Data collection via medical records and patient/physician questionnaires at 6 months post-initiation.

Main Results:

• 80 patients evaluated; initial mean PASI 8.3, DLQI 8.9.
• 58.8% continued apremilast at 6 months; discontinuation reasons included efficacy and safety.
• Patients continuing treatment achieved PASI75 (36.7%), with significant DLQI improvement (mean reduction >6 points).
• Common adverse events included diarrhea and nausea (56.3% of patients).

Conclusions:

• Apremilast demonstrated substantial improvements in quality of life and disease severity for psoriasis patients in Spanish clinical practice.
• Over one-third of patients achieved PASI75, indicating significant clinical benefit.
• Real-world outcomes suggest apremilast is an effective treatment option, even in patients with less severe skin involvement than seen in clinical trials.